Therapeutic regulation of apoptosis - Actual experiences and prospects of the development;Regulacja procesu apoptozy komórek w celach terapeutycznych - Dotychczasowe doświadczenia i perspektywy rozwoju

Acta Haematologica Polonica

Volumn 33, Issue 4, 2002, Pages 393-401

  Smolewski, Piotr ^a   Grzybowska, Olga ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Caspases inhibitors; Treatment

Indexed keywords

ALEMTUZUMAB; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE INHIBITOR; CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALZHEIMER DISEASE; APLASTIC ANEMIA; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; MYELODYSPLASIA; NEUROLOGIC DISEASE; NEUROPROTECTION; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; REVIEW;

EID: 0036984121     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45: 101-106.
2. Barni S, Pontiggia P, Vaccarone R, Silvotti MG, Pontiggia E, Mathe G. Hyperthermia-induced cell death by apoptosis in myeloma cells. Biomed Pharmacother 2001; 55: 170-173.
3. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. Cell death in health and disease: the biology and regulation of apoptosis. Semin Cancer Biol 1995; 6: 3-16.
4. Bilsand J, Roy S, Xanthoudakis S, Nicholson DW, Han Y, Grimm E, Hefti F, Harper SJ. Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci 2002; 22: 2637-2649.
5. Blagosklonny MV. Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug resistant cells but protects normal cells. Leukemia 2001; 15: 936-941.
6. Blogosklonny MV. The dilemma of apoptosis in myelodysplasia and leukemia: a new promise of therapeutic intervention. Leukemia 2000; 14: 2017-2018.
7. Boudard D, Sordet O, Vasselone C, Revol V, Bertheas MF, Freyssenet D, ViaUet A, Piselli S, Guyotat D, Campos L. Expression and activity of caspases-1 and -3 in myelodysplastic syndromes. Leukemia 2000; 14: 2045-2051.
8. Bouscary D, Chen Y, Guesnu M, Jondeau K, Viguie F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Activity of the caspase-3/CPP32 enzyme is increased in early stage myelodysplastic syndromes with excessive apoptosis. Exp Hematol 2000; 28: 784-791.
9. Byrd JC, Kitada S, Flinn JW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
10. Cinel I, Buyukafsar K, Cinel L, Polat A, Atici S, Tamer L, Oral U. The role of poly(ADP-ribose) synthetase inhibition in preventing endotoxemia-induced intestinal epithelial apoptosis. Pharmacol Res 2002; 46: 119.
11. Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koeberl DD, Amalfitano A, Boudtany RM. Flupirtine blocks apoptosis in batten patient lymph oblasts and in human post mitotic CLN3-and CLN2-deficirnt neurons. Ann Neurol 2002; 51: 448-466.
12. Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K, Zamai L, Miscia S, Zauli G. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001; 97: 2596-2603.
13. Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A, Robertson GS, Zamboni R, Nicholson DW, Holtzman DM. Selective, revesible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J Biol Chem 2002; 277: 30128-30136.
14. Holley CL, Olson MR, Colon-Ramos DA, Kornbluth S. Reaper eliminates IAP proteins through stimulated Iap degradation and generalized translational inhibition. Nat Cell Biol 2002; 4: 439-444.
15. Huang JQ, Radinovic S, Rezaiefar P, Black SC. In vivo myocardial infarct size reduction by caspase inhibitor administered after the onset of ischemia. Eur J Pharmacol 2000; 402: 139-142.
16. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibits apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) through suppression of caspases-8, -9, and -3 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 2002; 22: 269-279.
17. Lamothe B, Aggarwal BB. Ectopic expression of Bcl-2 and Bcl-xL inhibit apoptosis induced by TNF-related apoptosis inducing Ligand (TRAIL) through suppression of caspase-8, -7 and BID cleavage in human acute myelogenous leukemia cell line HL-60. J Interferon Cytokine Res 2002; 22: 269-279.
18. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Hale G, Waldman H, Mellstedt H, Osterborg A. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-PBL). Blood 2002; 100: 768-773.
19. Mori M, Terui Y, Tanaka M, Tomizuka H, Mishima Y, Ikeda M, Kasahara T, Uwai M, Ueda M, Inoue R, Itoh T, Yamada M, Hayasawa H, Furukawa Y, Ishizaka Y, Ozawa K, Hatake K. Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB. Cancer Res 2001; 61: 4414-4417.
20. Nakao K, Otsuki Y, Akao Y, Yto Y, Marukawa O, Tachibana S, Kawakami M, Sasaki S. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis. Med Electrone Microsc 2000; 33: 44-50.
21. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 2002; 29: 10-24.
22. Reed JC. Apoptosis and cancer: strategies for integrating programmed cell death. Seminars of Hematology 2000; 37: 9-16.
23. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-1430.
24. Scheller C, Sopper S, Ehrhardt C, Flory E, Chen P, Koutsilieri E, Ludwig s, Meulen Vt V, Jassoy C. Caspase inhibitors induce a switch from apoptotic to proinflammatory signaling in CD95-stimulated T lymphocytes. Eur J Immunol 2002; 32: 2471-2480.
25. Schmitt B, Wendnter CM, Bergmann M, Busch R, Franke A, Pasold R, Schlag R, Hopfinger G, Hiddeman W, Emmerich B, Hallek M. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3: 26-35.
26. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv 2000; 4: 281-286.
27. Shen X, Konig R. Post-thymic selection of peripheral CD4+T-lymphocytes on class II major histocompatibility antigen-bearing cells. Cell Mol Biol 2001; 47: 87-96.
28. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-546.
29. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
30. Vilvolic K, Sapunar D, Ilijic E, Mimica MD, England MA, Saraga-Babic M. Morphological characteristics of dying cells in axial structures of developing human embryos. Cells Tissues Organs 2001; 169: 347-354.
31. Wyllie A. Apoptosis and the regulation of cell numbers in normal and neoplastic tissues. Cancer Metast Rev 1992; 11: 95-103.